COMBINED RADIOCHEMOTHERAPY FOR POSTOPERATIVE RECURRENCE OF ESOPHAGEAL CANCER
COMBINED RADIOCHEMOTHERAPY FOR POSTOPERATIVE RECURRENCE OF ESOPHAGEAL CANCER
复制标题
DOI：
10.1136/gut.37.2.174
复制
发表时间：
1995-08-01
期刊：
影响因子：
24.5
通讯作者：
LAUNOIS, B
中科院分区：
文献类型：
--
作者：
RAOUL, JL;LEPRISE, E;LAUNOIS, B
食管癌术后复发是常见的。从1986年1月至1993年9月，31例患者（男性30例，女性1例，平均（SD）年龄：57.5（8.8）岁）在初次手术后15.0（12.6）个月发生局部复发（n = 24）、转移（n = 6）或两者兼有（n = 1）。所有病例均采用放化疗联合治疗。症状改善23例（74%），持续时间6.3(4)个月（不包括治疗期）。20例（65%）患者出现肿瘤缓解，其中8例（26%）完全缓解。6个月、1年、2年、3年生存率分别为70.7%、47.1%、17.1%、4.3%。综上所述，这些结果表明，联合治疗可对食管癌术后复发患者产生有益的症状效果，并可延长患者的生存期。
Postoperative recurrences are common after resection for oesophageal cancer. From January 1986 to September 1993 31 patients (30 males, one female, mean (SD) age: 57.5 (8.8) years) were treated for locoregional recurrence (n = 24), metastases (n = 6) or both (n = 1) occurring 15.0 (12.6) months after initial surgery. Radiotherapy and chemotherapy were combined in all cases. Symptomatic improvement was seen in 23 cases (74%) and lasted (excluding treatment period) for 6.3 (4) months. Objective tumoral response was seen in 20 patients (65%) including eight (26%) complete responses. Survival rates were at respectively six months, one, two, and three gears: 70.7%, 47.1%, 17.1%, 4.3%. In conclusion, these results show that combined therapy could have a beneficial symptomatic effect and can be associated with prolonged survival in patients with postoperative recurrences of oesophageal cancer.